Tvardi Therapeutics (TVRD) Receivables - Other (2015 - 2025)
Tvardi Therapeutics (TVRD) posted Receivables - Other of $1.0 million for Q1 2025, up 54.05% sequentially from $655000.0 in Q4 2024, and up 99.41% YoY from $506000.0 in Q1 2024.
Tvardi Therapeutics (TVRD) Receivables - Other (2015 - 2025) Analysis & Trends
Tvardi Therapeutics has reported Receivables - Other for 11 years, with the latest figure at $1.0 million in Q1 2025.
- Quarterly Receivables - Other rose 99.41% year-over-year to $1.0 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $1.0 million (up 99.41% YoY) and the FY2024 annual result came in at $4.1 million, up 636.58% from the prior year.
- Receivables - Other climbed to $1.0 million in Q1 2025 per TVRD's latest filing, from $655000.0 in the prior quarter.
- Over five years, Receivables - Other peaked at $20.0 million in Q3 2021 and troughed at -$19.9 million in Q4 2021.
- A 5-year average of $2.4 million and a median of $934000.0 in 2024 frame the typical range for Receivables - Other.
- The widest YoY moves for Receivables - Other: up 4238.74% in 2021, down 21042.11% in 2021.
- Over 5 years, Receivables - Other stood at -$19.9 million in 2021, then soared by 100.23% to $45000.0 in 2022, then tumbled by 2604.44% to -$1.1 million in 2023, then jumped by 158.12% to $655000.0 in 2024, then soared by 54.05% to $1.0 million in 2025.
- According to Business Quant data, Receivables - Other over the past three periods registered $1.0 million, $655000.0, and $934000.0 for Q1 2025, Q4 2024, and Q3 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Tvardi Therapeutics | 17.36 Mn | 17.36 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 1.01 Mn |
| Mar 31, 2025 | 1.01 Mn |
| Dec 31, 2024 | 655,000.00 |
| Dec 31, 2024 | 655,000.00 |
| Sep 30, 2024 | 934,000.00 |
| Sep 30, 2024 | 934,000.00 |
| Jun 30, 2024 | 764,000.00 |
| Jun 30, 2024 | 764,000.00 |
| Mar 31, 2024 | 506,000.00 |
| Mar 31, 2024 | 506,000.00 |
| Dec 31, 2023 | -1.13 Mn |
| Dec 31, 2023 | -1.13 Mn |
| Sep 30, 2023 | 1.68 Mn |
| Sep 30, 2023 | 1.68 Mn |
| Jun 30, 2023 | 10.12 Mn |
| Jun 30, 2023 | 10.12 Mn |
| Mar 31, 2023 | 6.07 Mn |
| Mar 31, 2023 | 6.07 Mn |
| Dec 31, 2022 | 45,000.00 |
| Dec 31, 2022 | 45,000.00 |